Adjuvant trastuzumab: a 10-year overview of its benefit.
about
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.Targeting immune checkpoints in breast cancer: an update of early results.A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer
P2860
Adjuvant trastuzumab: a 10-year overview of its benefit.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant trastuzumab: a 10-year overview of its benefit.
@en
Adjuvant trastuzumab: a 10-year overview of its benefit.
@nl
type
label
Adjuvant trastuzumab: a 10-year overview of its benefit.
@en
Adjuvant trastuzumab: a 10-year overview of its benefit.
@nl
prefLabel
Adjuvant trastuzumab: a 10-year overview of its benefit.
@en
Adjuvant trastuzumab: a 10-year overview of its benefit.
@nl
P2860
P1476
Adjuvant trastuzumab: a 10-year overview of its benefit
@en
P2093
Cinzia Solinas
Noam F Pondé
P2860
P356
10.1080/14737140.2017.1264876
P577
2016-12-05T00:00:00Z